Anika Therapeutics Inc. (NASDAQ:ANIK) shares increased 0.44% in last trading session and ended the day at $38.96. ANIK Gross Margin is 76.20% and its has a return on assets of 13.40%. Anika Therapeutics Inc. (NASDAQ:ANIK) quarterly performance is 24.27%.
Anika Therapeutics, Inc., (NASDAQ:ANIK) a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, announced the enrollment of the first patient in its pivotal HYALOFAST® FastTRACK Phase III clinical study.
Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) ended the last trading day at $9.72. Company weekly volatility is calculated as 4.18% and price to cash ratio as 2.88. Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) showed a weekly performance of 0.83%.
On 22 December, Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) announced that its Marketing Authorization Application (MAA) for oral Fanaptum® tablets has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of schizophrenia in adults.
On 29 December, FreeSeas Inc. (NASDAQ:FREE) shares moved down -4.00% and was closed at $0.02. FREE EPS growth in last 5 year was -14.90%. FreeSeas Inc. (NASDAQ:FREE) year to date (YTD) performance is -97.51%.
FreeSeas Inc. (NASDAQ:FREE), announced that at the special meeting of the Company’s shareholders held on December 28, 2015, the shareholders granted discretionary authority to the Company’s board of directors to (A) amend the Amended and Restated Articles of Incorporation of the Company to effect one or more consolidations of the issued and outstanding shares of common stock, pursuant to which the shares of common stock would be combined and reclassified into one share of common stock at a ratio within the range from 1-for-2 up to 1-for-60 (the “Reverse Stock Split”) and (B) determine whether to arrange for the disposition of fractional interests by shareholder entitled thereto, to pay in cash the fair value of fractions of a share of common stock as of the time when those entitled to receive such fractions are determined, or to entitle shareholder to receive from the Company’s transfer agent, in lieu of any fractional share, the number of shares of common stock rounded up to the next whole number, provided that, (X) that the Company shall not effect Reverse Stock Splits that, in the aggregate, exceeds 1-for-60, and (Y) any Reverse Stock Split is completed no later than the first anniversary of the date of the special meeting.
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) shares increased 2.19% in last trading session and ended the day at $7.93. INFI has a return on assets of -73.60%.
On December 17, 2015, Vito Palombella, Ph.D., Chief Scientific Officer of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) notified the Company of his decision to resign effective January 22, 2016. Dr. Palombella confirmed that he is not resigning as a result of any dispute or disagreement with the Company.
Cemtrex Inc. (NASDAQ:CETX) caters to the Industrial Goods space. It has a net profit margin of 4.90% and weekly performance is -14.99%. On the last day of trading company shares ended up at $2.41. Cemtrex Inc. (NASDAQ:CETX) distance from 50-day simple moving average (SMA50) is -12.56%.
On 18 December, Cemtrex Inc. (NASDAQ:CETX) reported Revenue increased by 19% to $56,887,389 for the twelve months ended in September 30, 2015 compared to $47,653,114 for the same period in 2014. Revenue increased 3% to $14,047,912, for the three months ended in September 30, 2015 compared to $13,686,428 for the same period in 2014. Net Income was up 6% to $2,833,116, equaling $.42 per share, in the twelve month period ended September 30, 2015 compared to an income of $2,693,994, or $.39 in the same period in 2014.
Leave a Reply